New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
11:32 EDTNSR, PWRD, QIWI, AZN, SHLD, DB, ARUN, WUBA, KERX, SPRDOptions with decreasing implied volatility:
Options with decreasing implied volatility: NSR KERX WUBA ARUN DB SHLD AZN QIWI PWRD SPLS
News For NSR;KERX;WUBA;ARUN;DB;SHLD;AZN;QIWI;PWRD;SPRD From The Last 14 Days
Check below for free stories on NSR;KERX;WUBA;ARUN;DB;SHLD;AZN;QIWI;PWRD;SPRD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 12, 2014
10:00 EDTARUNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
September 11, 2014
18:07 EDTARUNAruba Networks initiated with an Equal Weight at Morgan Stanley
11:07 EDTKERXOptions with decreasing implied volatility
Subscribe for More Information
09:57 EDTKERXSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
September 10, 2014
15:21 EDTAZNAstraZeneca has a conference call hosted by JPMorgan
Subscribe for More Information
11:43 EDTSHLDLand's End soars after better than expected Q2 results
Subscribe for More Information
11:22 EDTKERXOptions with decreasing implied volatility
Subscribe for More Information
07:11 EDTQIWIQIWI holder Mail.ru files to sell 2.165M shares of QIWI stock
Subscribe for More Information
September 9, 2014
12:02 EDTKERXOptions with decreasing implied volatility
Options with decreasing implied volatility: KERX CIEN FNSR PAY BKS PVH NAV BYI FTR JOY
September 8, 2014
16:18 EDTKERXOn The Fly: Closing Wrap
Subscribe for More Information
14:13 EDTAZNConnecticut AG tells FDA to speed up generic Nexium
A news release from the Connecticut Attorney General George Jepsen, dated September 4, says: In comments to a Citizen Petition filed with the FDA, Attorney General George Jepsen called on the federal agency to expeditiously end several years of delays preventing the sale of a generic form of the drug esomeprazole magnesium , esomeprazole, currently marketed under the brand name Nexium. Nexium is the second highest-selling pharmaceutical drug in the United States, and delays in approving generic versions have cost consumers and government healthcare payers billions of dollars. In his comments, Attorney General Jepsen alleges that an agreement between drug manufacturers Ranbaxy (RBXLY) and AstraZeneca Pharmaceuticals (AZN), Nexiumís brand-name manufacturer, has prevented other drug-makers from launching a generic version of the drug, ultimately harming all consumers by artificially inflating prices. Ranbaxy was first-to-file with the FDA for approval of a generic form of Nexium. AstraZeneca sued Ranbaxy for patent infringement, and the dispute was settled by an agreement that provided financial incentives for Ranbaxy to delay entry of its generic into the consumer market. Reference Link
10:42 EDTKERXOptions with decreasing implied volatility
Options with decreasing implied volatility: KERX CONN CIEN INSM FNSR PAY PVH SWY
10:06 EDTKERXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:29 EDTKERXKeryx downgraded to Underperform from Market Perform at FBR Capital
Subscribe for More Information
09:18 EDTKERXKeryx price target raised to $32 from $30 at Roth Capital
Subscribe for More Information
09:12 EDTKERXOn The Fly: Pre-market Movers
Subscribe for More Information
07:38 EDTKERXKeryx label for ferric citrate incrementally negative, says JPMorgan
JPMorgan says the approved label for Keryx's ferric citrate is incrementally negative given the lack of clear articulation of ESA/IV iron sparing data. The firm keeps an Overweight rating on the stock with a $24 price target, saying Keryx's 2024 patents are strong.
07:29 EDTDBNYSSA to hold a discussion
Russian and Central & Eastern European Capital Markets will be discussed at the NYSSA New York Conference Center on September 8 at 6 pm.
07:02 EDTAZNAstraZeneca announces availability of Bydureon pen 2mg
Subscribe for More Information
06:26 EDTKERXKeryx downgraded to Underperform from Market Perform at FBR Capital
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use